TapImmune Inc. (TPIV) Appoints Patrick D. Yeramian, MD, Consulting Medical Director To Lead Phase II Clinical Trials In Triple Negative Breast And HER2/neu Breast Cancer

SEATTLE, Feb. 23, 2015 /PRNewswire/ -- TapImmune, (OTCBB: TPIV), an immunotherapy company specializing in the development of immunotherapeutics for the treatment of cancer including metastatic disease, is pleased to announce Patrick D. Yeramian, MD, MBA, has been appointed Consulting Medical Director. He will lead TapImmune's clinical development programs for folate receptor alpha and Her2/neu multi-epitope cancer technologies.  These technologies have been evaluated in Phase I trials for safety and immune responses in women with breast or ovarian cancer.

Dr. Yeramian has over 25 years of experience in the pharmaceutical industry. He has supervised the clinical development of new drugs, biopharmaceuticals, cellular therapy agents, and vaccines as well as having held a prominent role in the approval of several new drug (metronidazole - Flagyl MR ®), biological (interferon alpha - Multiferon®, nafarelin Synarel®) and device  (Inerpan®) applications in the US in the EC and the granting of over 20 successful INDs and IMPDs.  Dr Yeramian is currently the Medical Director of the Vaccine and Gene Therapy Institute, Florida.  For the past 10 years, Dr. Yeramian has been a consulting Medical Director for emerging biotechnology companies in the areas of regulatory strategy, translational research, and early phase clinical trials.  Previously he served as Chief Medical Officer at Viragen, Inc. where he was responsible for development of global clinical and regulatory strategies and for implementation of clinical programs worldwide.   Earlier Dr. Yeramian also served as Director of clinical research at GD Searle where he supervised the clinical programs for antibiotics, antivirals, sepsis/thrombosis, and cancer vaccines.  Dr. Yeramian holds a Medical Degree from the University of Paris together with a Master of Clinical Science in experimental oncology and a Graduate Degree in molecular virology.  He also earned a Master of Business Administration from Rutgers University.  He completed his medical residency in oncology at the Saint-Louis Hospital in Paris.  

Dr. Yeramian has been working with TapImmune to design and execute Phase II clinical programs.  Duties include the design of clinical protocols, selection of clinical trial sites, recruitment of key opinion leaders as clinical advisors, and selection of external manufacturing and clinical resources.

"We are delighted to find someone with Dr. Yeramian's extensive clinical background to lead and coordinate the component parts for our Phase II clinical programs," said Glynn Wilson, Chairman & CEO of TapImmune. "Through his experience in clinical trial design and execution in immune-based therapeutics, he brings a unique skill set and expertise to TapImmune."

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastatic disease and infectious disease. The Company's vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details.

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

CONTACTS:

TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1-(866)-359-7541

PCG Advisory
Kirin M. Smith
Chief Operating Officer
+1-(646)-863-6519

Sean Leous
Chief Communications Officer
+1-(646)-863-8998

www.pcgadvisory.com

J. Streicher Capital, LLC
Robert Giordano
+1-917-327-3938

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.